Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines - PubMed (original) (raw)
. 1987 Jan 1;47(1):145-9.
- PMID: 3791201
Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines
A A Creasey et al. Cancer Res. 1987.
Abstract
We investigated optimal conditions for cytotoxicity to tumor cell lines by recombinant human tumor necrosis factor (rhTNF) and the effect of amino-terminal deletions on the bioactivity of the rhTNF molecule. Two of four deletion muteins (-4 and -7) of rhTNF exhibit 2- to 3-fold enhancement of cytotoxicity/cytostasis against a variety of human carcinomas, a fibrosarcoma, and a melanoma cell line with no toxicity on normal fibroblastic and epithelial cultures. Of the two other muteins the -8 displayed equivalent and/or increased cytotoxicity/cytostasis while the -10 was consistently less cytotoxic than the parent on the same cell lines. Continuous exposure to TNF for greater than or equal to 96 h led to maximal cytotoxicity to tumor lines (99.99% with L929 cells) with no evidence of recovery. Pretreatment with actinomycin D (0.003-10 micrograms/ml for 1 h) rendered 82% of rhTNF-resistant cell lines (both tumor and normal) susceptible to its cytotoxic action within 24 h. However, the highest nontoxic concentrations of Actinomycin D necessary for rendering normal cell lines susceptible to TNF action were about 10-3000-fold higher than those necessary for converting resistant tumor cell lines. Similarly, preinfection of L929 cells with vesicular stomatitis virus (multiplicity of infection, 10(-2)-10(-4) for 1 h) rendered the cells 2-10-fold more susceptible to the cytotoxic action of rhTNF in 18 h. Our data suggest that rhTNF and its muteins represent potentially useful anticancer agents; however, adequate dosing and prolonged exposure may be critical in demonstrating cytotoxicity/cytostasis. The data also show that although normal and tumor cell lines became susceptible to cytotoxicity by rhTNF and actinomycin D, combination therapy of the two agents may be possible at defined concentrations.
Similar articles
- Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor.
Zimmerman RJ, Chan A, Leadon SA. Zimmerman RJ, et al. Cancer Res. 1989 Apr 1;49(7):1644-8. Cancer Res. 1989. PMID: 2924312 - [Anti-tumor effect of human recombinant TNF].
Watanabe N, Niitsu Y, Neda H, Yamauchi N, Maeda M, Kuriyama H, Sone H. Watanabe N, et al. Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):780-7. Gan To Kagaku Ryoho. 1988. PMID: 3291772 Review. Japanese. - Tumor cytotoxic activity of HGF-SF.
Higashio K, Shima N. Higashio K, et al. EXS. 1993;65:351-68. EXS. 1993. PMID: 8380742 Review.
Cited by
- Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.
Fujimoto S, Kobayashi K, Takahashi M, Konno C, Kokubun M, Ohta M, Shrestha RD, Kiuchi S. Fujimoto S, et al. Br J Cancer. 1992 Jan;65(1):33-6. doi: 10.1038/bjc.1992.6. Br J Cancer. 1992. PMID: 1733439 Free PMC article. - Apoptosis induced by tumor necrosis factor-alpha in rat hepatocyte cell lines expressing hepatitis B virus.
Guilhot S, Miller T, Cornman G, Isom HC. Guilhot S, et al. Am J Pathol. 1996 Mar;148(3):801-14. Am J Pathol. 1996. PMID: 8774135 Free PMC article. - In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours.
Kallinowski F, Schaefer C, Tyler G, Vaupel P. Kallinowski F, et al. Br J Cancer. 1989 Oct;60(4):555-60. doi: 10.1038/bjc.1989.312. Br J Cancer. 1989. PMID: 2803925 Free PMC article. - A high molecular weight component of the human tumor necrosis factor receptor is associated with cytotoxicity.
Creasey AA, Yamamoto R, Vitt CR. Creasey AA, et al. Proc Natl Acad Sci U S A. 1987 May;84(10):3293-7. doi: 10.1073/pnas.84.10.3293. Proc Natl Acad Sci U S A. 1987. PMID: 3033642 Free PMC article. - Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.
Marincola FM, Ettinghausen S, Cohen PA, Cheshire LB, Restifo NP, Mulé JJ, Rosenberg SA. Marincola FM, et al. J Immunol. 1994 Apr 1;152(7):3500-13. J Immunol. 1994. PMID: 8144931 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources